Brijendra Singh joins Emcure Pharmaceuticals as executive vice-president

MUMBAI: Emcure Pharmaceuticals has appointed Brijendra Singh as executive vice-president, roping in one of the industry’s most seasoned commercial leaders as it sharpens its focus on scale, launches and market expansion.

Singh brings more than 40 years of experience across pharmaceutical sales, product launches and market strategy, with a career built on taking therapies from pipeline to patients at scale. He joins Emcure after a long stint at Lupin, where he most recently served as vertical head and senior vice-president for sales and marketing across cardiology, diabetes, metabolic and ophthalmology portfolios.

At Lupin, Singh led teams of more than 1,000 professionals and managed a business worth over Rs 800 crore. He played a central role in launching and scaling the company’s diabetes care division, now ranked No. 1 in sales at Lupin and among the top three therapy areas in the Indian pharmaceutical market.

Singh’s career spans every rung of the sales ladder, from medical sales representative to national and regional leadership roles, giving him a rare ground-up understanding of execution in India’s complex pharma markets.

As Emcure looks to accelerate growth across chronic and speciality therapies, Singh’s appointment signals a renewed push for scale, speed and on-ground excellence.